General discussion, page-16568

Hey Ashfield. Question for you (or anyone else who has the answer).

What would you do in Joel's position to improve short term SP?

Speeding up the clinical trials is not an option. This takes time. Heavily regulated and must meet all compliance checkpoints to receive fda approval. No short cuts here, would you agree?

Sticking to the ASX? We've been fumbling around in this market for months. Absolutely zero interest from investors despite a healthy flow of positive announcements. There is enough evidence to suggest NASDAQ is the right move (with some short term pain preceeding it). In fact I would argue that this was always on the cards, given the low liquidity provided to NSDAQ during the original move.

Or do you still blame some of the other big decisions, ApirX acqusition (largest IP portfolio purchased with scrip at a massive premium to todays SP) or the capital raise at 20c which has allowed us to fund the first dedicated psychedelic clinic in Australia?

Which of these decisions was the catalyst in your eyes, or is it a combination of all of them? And what would you do differently in Joel's position to influence SP today?